News & Media

Take a look inside our world

Press Releases

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class P...

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potent

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-...

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Prop...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarte...

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Pro...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept...

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculi...

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025...

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Fina

Contacts for Media Inquiries

Kelley Dougherty

North America

+1-973-658-0237
Kelley.Dougherty@tevapharm.com

Eden Klein

Israel & Corporate

+972-3-9062645
Eden.Klein@teva.co.il

Fiona Cohen

Europe

fiona.cohen@tevaeu.com


Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Feature stories

“Real Progress Comes Not from Extraordinary Moments but from the Everyday”

“Real Progress Comes Not from Extraordinary Moments but from the Everyday”

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com

View our Social Media Guidelines

Learn more